METRONIDAZOLE- metronidazole cream
Harris Pharmaceutical, Inc.


Metronidazole Topical Cream contains metronidazole, USP, at aconcentration of 7.5 mg per gram (0.75%) in an emollient cream consisting of emulsifying wax, sorbitol solution, glycerin, isopropyl palmitate, benzyl alcohol, lactic acid and/or sodium hydroxide to adjust pH, and purified water. Metronidazole is a member of the imidazole class of anti-bacterial agents and isclassified therapeutically as an antiprotozoal and antibacterial agent. Chemically,metronidazole is 2-methyl-5-nitro-1H -imidazole-1-ethanol. The molecular formula is C6 H9 N3 O3 and molecular weight is 171.16. Metronidazole is represented bythe following structural formula:

Metronidazole Chemical StructureMetronidazole Chemical StructureMetronidazole Carton


The mechanisms by which metronidazole acts in the treatment of rosacea are unknown, but appear to include an anti-inflammatory effect.


Metronidazole Topical Cream is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea.


Metronidazole Topical Cream is contraindicated in individuals with a history of hypersensitivity to metronidazole, or other ingredients of the formulation.



Topical metronidazole has been reported to cause tearing of the eyes. Therefore, contact with the eyes should be avoided. If a reaction suggesting local irritation occurs, patients should be directed to use the medication less frequentlyor discontinue use. Metronidazole is a nitroimidazole and should be used with care in patients with evidence of, or history of blood dyscrasia.

Information for patients:

This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.

Drug Interactions:

Oral metronidazole has been reported to potentiate the anticoagulant effect of warfarin and coumarin anticoagulants, resulting in a prolongation of prothrombin time. The effect of topical metronidazole on prothrombintime is not known.

Carcinogenesis, mutagenesis, impairment of fertility:

Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats but not in studies involving hamsters.

Metronidazole has shown evidence of mutagenic activity in several in vitro bacterial assay systems. In addition, a dose-response increase in the frequency of micronuclei was observed in mice after intraperitoneal injections and an increase in chromosome aberrations have been reported in patients with Crohn’s disease who were treated with 200-1200 mg/day of metronidazole for 1 to 24 months. However, no excess chromosomal aberrations in circulating human lymphocytes have been observed in patients treated for 8 months.


Teratogenic effects: Pregnancy category B

There are no adequate and well-controlled studies with the use of Metronidazole Topical Cream in pregnant women. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral metronidazole in rats or mice. However, because animal reproduction studies are not always predictive of human response and since oral metronidazole has been shown to be a carcinogen in some rodents, this drug should be used during pregnancy only if clearly needed.

Nursing mothers:

After oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. Even though blood levels are significantly lower with topically applied metronidazole than those achieved after oral administration of metronidazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric use:

Safety and effectiveness in pediatric patients have not been established.


In controlled clinical trials, the total incidence of adverse reactions associated with the use of Metronidazole Topical Cream was approximately10%. Skin discomfort (burning and stinging) was the most frequently reported event followed by erythema, skin irritation, pruritus and worsening of rosacea. All individual events occurred in less than 3% of patients.

The following additional adverse experiences have been reported with the topical use of metronidazole: dryness, transient redness, metallic taste, tingling or numbness of extremities and nausea.


Apply and rub in a thin layer of Metronidazole Topical Cream twice daily, morning and evening, to entire affected areas after washing.

Areas to be treated should be washed with a mild cleanser before application. Patients may use cosmetics after application of Metronidazole Topical Cream.


Metronidazole Topical Cream, 0.75% is supplied in a 45 g tube — NDC 67405-110-45.

STORAGE conditions:

Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

Manufactured for:
HARRIS Pharmaceutical, Inc.
Fort Myers, FL 33908
877-RX4-DERM •
By G&W Laboratories, Inc.
South Plainfield, NJ 07080


NDC 67405-110-45

Metronidazole Topical Cream 0.75%

NET WT 45 g Rx Only


Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

Usual dosage: Apply a thin layer to entire affected areas after washing. Use morning and evening or as directed by physician. Avoid application close to the eyes.

Each gram contains: Active: metronidazole 0.75% (7.5 mg). Inactive: emulsifying wax, sorbitol solution, glycerin, isopropyl palmitate, benzyl alcohol, lactic acid and/or sodium hydroxide to adjust pH, and purified water.

See end panel for lot number and expiration date.

Manufactured for:HARRIS
Pharmaceutical, Inc.
Fort Myers, FL 33908
By G&W Laboratories, Inc.
South Plainfield, NJ 07080

Metronidazole Carton
(click image for full-size original)
metronidazole cream
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:67405-110
Route of Administration TOPICAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Metronidazole (Metronidazole) Metronidazole 7.5 mg in 1 g
Inactive Ingredients
Ingredient Name Strength
Isopropyl Palmitate
Benzyl Alcohol
Lactic Acid
Sodium Hydroxide
# Item Code Package Description Multilevel Packaging
1 NDC:67405-110-45 45 g in 1 TUBE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA077549 03/13/2008
Labeler — Harris Pharmaceutical, Inc. (617204370)

Revised: 11/2009 Harris Pharmaceutical, Inc.

All resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.